Bobby Gaspar - 04 Oct 2022 Form 4 Insider Report for Orchard Therapeutics plc

Role
Chief Executive Officer, Director
Signature
/s/ Frank E. Thomas, as Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
04 Oct 2022
Net transactions value
$0
Form type
4
Filing time
06 Oct 2022, 18:11:07 UTC
Previous filing
03 Jun 2022
Next filing
03 Mar 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ORTX Stock Option (Right to Buy) Disposed to Issuer $0 -50,000 -100% $0.000000* 0 04 Oct 2022 Ordinary Shares 50,000 $12.54 Direct F1, F2, F3
transaction ORTX Stock Option (Right to Buy) Award $0 +50,000 $0.000000 50,000 04 Oct 2022 Ordinary Shares 50,000 $0.5800 Direct F1, F2, F3
transaction ORTX Stock Option (Right to Buy) Disposed to Issuer $0 -200,000 -100% $0.000000* 0 04 Oct 2022 Ordinary Shares 200,000 $13.58 Direct F1, F3, F4
transaction ORTX Stock Option (Right to Buy) Award $0 +200,000 $0.000000 200,000 04 Oct 2022 Ordinary Shares 200,000 $0.5800 Direct F1, F3, F4
transaction ORTX Stock Option (Right to Buy) Disposed to Issuer $0 -300,000 -100% $0.000000* 0 04 Oct 2022 Ordinary Shares 300,000 $7.05 Direct F1, F3, F5
transaction ORTX Stock Option (Right to Buy) Award $0 +300,000 $0.000000 300,000 04 Oct 2022 Ordinary Shares 300,000 $0.5800 Direct F1, F3, F5
transaction ORTX Stock Option (Right to Buy) Disposed to Issuer $0 -850,000 -100% $0.000000* 0 04 Oct 2022 Ordinary Shares 850,000 $5.98 Direct F1, F3, F6
transaction ORTX Stock Option (Right to Buy) Award $0 +850,000 $0.000000 850,000 04 Oct 2022 Ordinary Shares 850,000 $0.5800 Direct F1, F3, F6
transaction ORTX Stock Option (Right to Buy) Disposed to Issuer $0 -55,006 -100% $0.000000* 0 04 Oct 2022 Ordinary Shares 55,006 $5.98 Direct F1, F3, F7
transaction ORTX Stock Option (Right to Buy) Award $0 +55,006 $0.000000 55,006 04 Oct 2022 Ordinary Shares 55,006 $0.5800 Direct F1, F3, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On October 4, 2022, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
F2 The shares subject to this option vest in equal monthly installments over the four years after January 16, 2019.
F3 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F4 The shares subject to this option vest in equal monthly installments over the four years after January 2, 2020.
F5 The shares subject to this option vest in equal monthly installments over the four years after April 1, 2020.
F6 The shares subject to this option vest in equal monthly installments over the four years after February 1, 2021.
F7 The shares subject to this option are fully vested as of the date hereof.